Predictive values of bilirubin for in-hospital adverse events in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention

Ying, Chen; Liu, Cun-Fei; Guo, De-Qun; Du, Zheng-Ren; Wei, Yan-Jin

doi:10.1016/j.clinsp.2023.100306

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, further research is warranted to explore longterm outcomes and the impact of bilirubin levels post-discharge in STEMI patients. Overall, these findings emphasize the importance of liver function markers, particularly bilirubin, in assessing and managing HF and STEMI patients [101,102].…”

Section: Bilirubinmentioning

confidence: 72%

“…Furthermore, the ALBI score remains independently associated with mortality in chronic HF patients, suggesting its utility as a risk assessment tool [101,102]. In ST-elevation MI (STEMI) patients undergoing primary percutaneous coronary intervention (PCI), elevated bilirubin levels are independently associated with an increased risk of in-hospital Major Adverse Cardiac Events (MACEs), indicating its potential as a predictive biomarker for adverse cardiac events [102]. However, further research is warranted to explore longterm outcomes and the impact of bilirubin levels post-discharge in STEMI patients.…”

Section: Bilirubinmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure

Wróbel-Nowicka,

Wojciechowska,

Jacheć

et al. 2024

Medicina

View full text Add to dashboard Cite

Heart failure (HF) remains a major medical and social problem. The NT-pro-brain natriuretic peptide (NT-proBNP) and its active form, brain-type natriuretic peptide (BNP), in a simple blood test are the gold-standard biomarkers for HF diagnosis. However, even good biomarkers such as natriuretic peptides fail to predict all the risks associated with HF due to the diversity of the mechanisms involved. The pathophysiology of HF is determined by numerous factors, including oxidative stress, inflammation, neuroendocrine activation, pathological angiogenesis, changes in apoptotic pathways, fibrosis and vascular remodeling. High readmission and mortality rates prompt a search for new markers for the diagnosis, prognosis and treatment of HF. Oxidative-stress-mediated inflammation plays a crucial role in the development of subsequent changes in the failing heart and provides a new insight into this complex mechanism. Oxidative stress and inflammatory biomarkers appear to be a promising diagnostic and prognostic tool in patients with HF. This systematic review provides an overview of the current knowledge about oxidative stress and inflammation parameters as markers of HF.

show abstract

Section: Bilirubinmentioning

confidence: 72%